Scarica l'app Stockscreener
0.7652
3.55%
-0.0282
Dopo l'orario di chiusura:
.79
0.0248
+3.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CTXR Giù?
Forum
Previsione
Frazionamento azionario
Citius Pharmaceuticals Inc Borsa (CTXR) Ultime notizie
Can Citius Pharmaceuticals Inc. stock continue upward trendTrade Exit Summary & Verified Momentum Watchlists - mfd.ru
Leonard Mazur: The Adventures of a Serial Entrepreneur - Pharmaceutical Executive
Citius Pharmaceuticals Q1 Earnings Report: What Investors Need to Know - Benzinga
Citius Pharmaceuticals Posts First Revenue Amid Listing Risk - TipRanks
Citius Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
CTXR: First revenue of $3.9M from LYMPHIR launch, narrowing net loss and strong pipeline progress - TradingView
Citius Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Citius Pharmaceuticals reports first revenue of $3.9 mln - TradingView
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - Nasdaq
Risk Check: Should you buy the dip on ImmuCell CorporationWeekly Trend Summary & Precise Swing Trade Alerts - baoquankhu1.vn
Citius Oncology Signs Exclusive Distribution Agreement with Uniphar - Intellectia AI
Market Review: Is Citius Pharmaceuticals Inc a cyclical or defensive stockPortfolio Performance Report & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Analysts Expect Breakeven For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Before Long - simplywall.st
Does Citius Pharmaceuticals Inc. align with a passive investing strategyTrade Volume Report & Daily Technical Forecast Reports - mfd.ru
Aug PostEarnings: Is IMRN subject to activist investor interest2025 Historical Comparison & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar - Finviz
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - Morningstar
What is the earnings history of Citius Pharmaceuticals IncJuly 2025 Trends & Low Drawdown Investment Ideas - baoquankhu1.vn
Risk Check: What is Citius Pharmaceuticals Incs 5 year growth outlookWeekly Profit Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
VIX Spike: Is Citius Pharmaceuticals Inc a potential multi baggerJuly 2025 WrapUp & Smart Allocation Stock Tips - baoquankhu1.vn
Weekly Earnings: Can Howard Hughes Holdings Inc deliver consistent EPS growthEarnings Overview Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Citius Pharmaceuticals announces registered direct offering of $15.8 million - MSN
Geopolitics Watch: Is Citius Pharmaceuticals Inc benefiting from interest rate changesTrade Performance Summary & Short-Term Trading Alerts - baoquankhu1.vn
What technical charts say about Citius Pharmaceuticals Inc. stock2025 Earnings Surprises & Weekly Top Stock Performers List - bollywoodhelpline.com
Setup Watch: Whats next for VGASW stock2025 Market Sentiment & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Published on: 2026-01-13 01:39:15 - ulpravda.ru
Can Citius Pharmaceuticals Inc. stock attract ESG capital inflowsEarnings Performance Report & Stepwise Trade Signal Implementation - ulpravda.ru
Will Citius Pharmaceuticals Inc. (47N0) stock outperform Dow Jones2025 Geopolitical Influence & Entry and Exit Point Strategies - Улправда
What hedge fund moves indicate for Citius Pharmaceuticals Inc. (47N0) stockShare Buyback & Stepwise Trade Signal Implementation - ulpravda.ru
Will Citius Pharmaceuticals Inc. stock continue upward momentumJuly 2025 Drop Watch & Technical Entry and Exit Alerts - Улправда
Is Citius Pharmaceuticals Inc. stock a top momentum playPortfolio Performance Report & Accurate Entry and Exit Point Alerts - ulpravda.ru
How Citius Pharmaceuticals Inc. (47N0) stock expands through international marketsMarket Growth Report & Consistent Profit Trade Alerts - Улправда
Can Citius Pharmaceuticals Inc. (47N0) stock resist broad market declinesJuly 2025 Big Picture & High Conviction Investment Ideas - Улправда
Will Citius Pharmaceuticals Inc. stock maintain dividend yieldJuly 2025 Sentiment & Weekly Stock Breakout Alerts - ulpravda.ru
User | poteaudailynews.comCitius Pharmaceuticals, Inc.Common Stock (Nasdaq:CTXR) Stock Quote - FinancialContent
Portfolio Update: Can Citius Pharmaceuticals Inc 47N0 stock resist broad market declinesJuly 2025 Chart Watch & Safe Capital Allocation Plans - Bộ Nội Vụ
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - GuruFocus
Citius Pharmaceuticals regains Nasdaq compliance - MSN
Citius Oncology announces pricing of $9 million public offering - MSN
Press Release: Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - 富途牛牛
Fibonacci Retracement Aligns with Support in Thomas Scott India LimitedAnalyst Upgrades & Small Capital Trading Tips - earlytimes.in
Is Citius Pharmaceuticals Inc 47N0 a good long term investmentMarket Sentiment Report & Free Long-Term Investment Planning - earlytimes.in
Citius Pharmaceuticals Inc (CTXRW) Fundamental Analysis - Meyka
Market Outlook: What dividend safety score for Citius Pharmaceuticals Inc stockAnalyst Downgrade & Risk Managed Investment Strategies - Bộ Nội Vụ
CITIUS PHARMACEUTICALS Q4 2025 Earnings Preview: Recent $CTXR Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Dow Gains Over 100 Points; US Jobless Claims Decline - Benzinga
Stock Market Today: Dow Jones, Nasdaq Futures Slip On Christmas Eve Despite Strong Q3 GDP Report— UiPath, AST SpaceMobile, Ramaco In Focus (UPDATED) - Benzinga
Stock Market Today: Dow Jones, S&P 500 Futures Drop On Christmas Eve Despite Strong Q3 GDP Report—UiPath, AST SpaceMobile, Ramaco Resources In Focus - Sahm
Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why - Benzinga
UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday - Benzinga
Citius Pharmaceuticals Inc. Full Year Loss Decreases - Nasdaq
Citius Pharmaceuticals (CTXR) Reports Wider Annual Loss - GuruFocus
Citius Pharma launches cancer immunotherapy LYMPHIR in the U.S. By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals, Inc. reports fiscal year 2025 financial results and provides business update - marketscreener.com
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update - TradingView — Track All Markets
Citius Oncology Transitions to Commercial Stage: Analyzing the 10-K Filing and the 2026 Outlook for LYMPHIR - FinancialContent
Citius Pharmaceuticals (CTXR) Reports Earnings Miss with Increas - GuruFocus
Citius Pharma launches cancer immunotherapy LYMPHIR in the U.S. - Investing.com
CTXR: LYMPHIR's U.S. launch marks a pivotal year, with strong capital raises and ongoing pipeline progress - TradingView — Track All Markets
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - WV News
Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView — Track All Markets
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 - marketscreener.com
How interest rate cuts could boost Citius Pharmaceuticals Inc. stockShort Setup & Stock Portfolio Risk Management - Улправда
Why Citius Pharmaceuticals Inc. stock remains resilientPortfolio Performance Report & Technical Pattern Based Buy Signals - Улправда
Is Citius Pharmaceuticals Inc. (47N0) stock a safe buy pre earningsExit Point & Daily Oversold Bounce Ideas - Bölüm Sonu Canavarı
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):